Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Cisplatin 55Radiotherapy 33Cetuximab 25Paclitaxel 23Carboplatin 23Radiotherapy, Intensity-Modulated 21pembrolizumab 19Docetaxel 17Fluorouracil 16Nivolumab 14Drug Therapy 11Radiation 9Erlotinib Hydrochloride 8Blood Specimen Collection 8durvalumab 7Magnetic Resonance Spectroscopy 7Surveys and Questionnaires 6atezolizumab 5Surgical Procedures, Operative 5Radiosurgery 5Esophagectomy 5Chemoradiotherapy 5olaparib 4dacomitinib 4Leucovorin 4Cyclophosphamide 4Capecitabine 4Biopsy 4Afatinib 4fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Squamous Cell × nanocis × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡